Drug Trial Radar · NCT06021574
A First-in-human Study of a Novel Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody
Last checked: Nov 20, 2026Latest source record: Sep 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Jun 28, 2019
Primary completion
Jan 6, 2020
Study completion Jan 6, 2020
Sponsor
- Lead sponsor
- The Affiliated Hospital of Qingdao UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Beijing VDJBio Co., LTD.
- First posted
- Sep 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to study the tolerability, safety, pharmacokinetics and immunogenicity of investigational drug in healthy subjects. The main questions it aims to answer are: * Safety and tolerability of investigational drug. * pharmacokinetics and immunogenicity of investigational drug. Participants will receive a single intravenous administration of investigational drug or placebo. Blood samples are collected at specified time points.
Conditions
- Healthy
Interventions
VDJ001Drug
a novel recombinant humanized anti-interleukin-6 receptor monoclonal antibody
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- adverse eventsTime frame: up to 57 days
- Pharmacokinetics-AUC0-tTime frame: up to 57 days
- Pharmacokinetics-AUC0-infTime frame: up to 57 days
- Pharmacokinetics-CmaxTime frame: up to 57 days
- Pharmacokinetics-TmaxTime frame: up to 57 days
- Pharmacokinetics-t1/2Time frame: up to 57 days
- Pharmacokinetics-VzTime frame: up to 57 days
- Pharmacokinetics-CLzTime frame: up to 57 days
- Pharmacokinetics- λzTime frame: up to 57 days
- Pharmacokinetics-MRT0-tTime frame: up to 57 days
- Pharmacokinetics-MRT0-infTime frame: up to 57 days
- Anti-Drug antibody (ADA)Time frame: up to 57 days
- Neutralizing antibodies (Nab)Time frame: up to 57 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
the Affliated Hospital of Qingdao University
Qingdao, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.